Search Results

Site Search

Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D. - Insights

David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely...

Panel Boosts Therapeutic Monitoring of IBD Drug: Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D. - Insights

Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D., explain how Mayo Clinic Laboratories' unique risankizumab panel measures levels of both that drug and its antibodies in patients' blood. The results can better guide the management of...

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC - Insights

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related...

Unique testing helps identify cause of sudden cardiac death: Linnea Baudhuin, Ph.D., and Kate Kotzer, M.S., CGC - Insights

Linnea Baudhuin, Ph.D., and Kate Kotzer, M.S., CGC, describe how Mayo Clinic Laboratories' postmortem genetic tests can provide answers after a sudden unexplained cardiac death. Test results are important for managing family members' risk...

Genetic Tests Identify Risk of Irinotecan-Induced Toxicity: John Logan Black, M.D. - Insights

John Logan Black, M.D., explains how Mayo Clinic Laboratories' UGT1A1 tests (Mayo IDs: U1A1Q and UGTFZ) identify genetic variants that increase the risk of potentially life-threatening reactions to irinotecan, a chemotherapy agent.

Hypermethylation Test Guides Lynch Syndrome Care: Megan Hoenig, M.S., M.P.H., CGC - Insights

Megan Hoenig, M.S., M.P.H., CGC, explains how Mayo Clinic Laboratories' unique hypermethylation analysis (Mayo ID: MLHPB) provides critical adjunct information for managing Lynch syndrome. That genetic condition increases the risk for many...

Updated assay guides diagnosis of autoimmune liver disease: Anne Tebo, Ph.D. - Insights

Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' updated ALDG2 assay helps with the evaluation of patients with suspected autoimmune liver disease. The panel also helps with the evaluation of liver disease of unknown etiology.

Panel offers proactive drug monitoring for IBD: Maria Willrich, Ph.D., and Melissa Snyder, Ph.D. - Insights

Maria Willrich, Ph.D., and Melissa Snyder, Ph.D., describe Mayo Clinic Laboratories' panel for proactive therapeutic drug monitoring of patients with inflammatory bowel disease. The panel expands options for clinicians assessing patients'...

MAG Antibody Testing [Test in Focus] - Insights

John Mills, Ph.D., explains Mayo Clinic Laboratories’ approach to MAG antibody testing. The ELISA-based assay uses higher reference ranges and human MAG antigen to detect MAG antibodies, which are associated with a rare, hard-to-treat...

Leveraging Lessons from the Past - Insights

Sharing lessons learned from past process improvement and other projects conducted at Mayo Clinic.